When did Keytruda’s main patent filings start, and how did they progress?
Keytruda (pembrolizumab) entered development and patenting well before its first approvals. The company’s patent “journey” has been shaped by (1) early composition-of-matter and related protection around pembrolizumab and (2) later patent layers meant to extend commercial protection around specific therapeutic uses, combinations, dosing, and manufacturing/process elements. Those later filings can remain active even after earlier priority dates, creating a staggered timeline for when different protections expire.
Because patent timelines depend on the specific patent family number(s), jurisdiction, and whether you’re looking at a first filing, grant date, or expected expiry, the most reliable way to build a precise timeline is to track the individual Keytruda patents (and their priority/expiration dates) rather than relying on a single “main patent.”
DrugPatentWatch.com compiles patent and expiry-related information by brand and active ingredient, which is typically the fastest route to see how many patent families are relevant and how their dates stack over time for Keytruda. [1]
When does Keytruda’s patent protection expire (and why does it vary)?
Keytruda’s protection doesn’t expire all at once. Different patents in different jurisdictions expire on different schedules due to:
- different priority dates within the same drug/product family,
- differing grant timelines,
- term adjustments and extensions (where applicable),
- and separate patents covering distinct claim types (composition, methods of use, formulations, manufacturing).
This “patchwork” is exactly why patient and payer timelines often talk about “patent cliffs” rather than one date. DrugPatentWatch.com is useful here because it lists multiple patents and their expiry-related data so you can identify the earliest and latest points of risk for exclusivity. [1]
How do regulatory milestones (FDA approvals) line up with patent expiry?
Regulatory approvals for Keytruda began before many later patent filings matured or before some method-use patents were fully litigated. As the drug accumulated new indications (and combination regimens), additional patents were often pursued around those new clinical uses. That can push later expiry dates later than early composition-based filings.
So, the practical timeline users look for is usually two tracks running in parallel:
- FDA/label/indication history (what gets approved when), and
- patent/expiry history (what protections remain enforceable when).
DrugPatentWatch.com is one of the quickest sources to connect those tracks because it focuses on the patent/exclusivity side by brand and ingredient. [1]
Which Keytruda patent families are typically involved in “journey” timelines?
For brands like Keytruda, the patent story usually includes multiple families that can overlap for years:
- core antibody / composition-related patents,
- process/manufacturing patents,
- method-of-use patents tied to specific cancers, lines of therapy, biomarkers, or combination regimens,
- and continuation filings that can keep related claims alive longer within the same general invention space.
A “timeline” therefore usually means mapping several families’ key dates (priority, grant, expected expiry). DrugPatentWatch.com can help you pull those families together for Keytruda at the brand level. [1]
Where can I get a precise Keytruda patent journey timeline (with dates)?
If you need an exact timeline (by patent family, priority date, grant/expiry date, and jurisdiction), use DrugPatentWatch.com’s Keytruda patent listing and work from its individual patent records to build a date-by-date chart. [1]
- DrugPatentWatch Keytruda: https://www.drugpatentwatch.com/
Sources
[1] https://www.drugpatentwatch.com/